The QualityStocks Daily Friday, August 2nd, 2019

Today's Top 3 Investment Newsletters

QualityStocks (WCCP) +152.74%

BUYINS.NET (APHA) +40.96%

MarketBeat (BL) +31.66%

The QualityStocks Daily Stock List

Verus International, Inc. (VRUS)

Transparent Traders, Last10k, Stockopedia, Insider Tracking, Market Screener, Stockwatch, InvestorsHangout, Market Wire News, TradingView, Stockhouse, News Planets, InvestorsHub, GlobeNewswire, and Simply Wall St reported earlier on Verus International, Inc. (VRUS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Verus International, Inc. operates a global food subsidiary (Verus Foods) that sells branded consumer products to customers around the world. The Company has developed premier food products sourced in the U.S. and exported them internationally. Verus works very closely with its local and international suppliers to deliver the finest food products at reasonable prices.

The Company lists on the OTC Markets Group’s OTCQB. Verus International has its corporate headquarters in Gaithersburg, Maryland. It was previously known as RealBiz Media Group, Inc. The Company changed its name to Verus International, Inc. in October of 2018.

Verus centers on the regional sensitivities and dietary requirements in the markets that it exports to. The Company’s dedication is to quality control and food safety. It closely monitors every step of the process meticulously. This is to ensure its strict food quality and production guidelines are met. This is from sourcing, production, packing, to shipping.

Verus International’s products include Condiments, Meat & Poultry, Ice Creams, Vegetables/French Fries, Commodities, and Candy. Commodities include Pulses & Legumes, Grains, as well as Rice. Verus Foods distributes and delivers its food products via an array of channels. This includes wholesale, van sales, retail and HORECA (Hotel/Restaurant/Café).

For Q2 2019, Revenue set an all-time record of $2.9 million. This represents an increase of 153 percent over the $1.2M reported in Q2/18. Verus’ Gross Margin was roughly 15.4 percent, within the higher historical range for the current product mix; up 348 basis points versus Q2/18. Net Income reflected a profit of $2.2 million. On a pro-forma basis, the Company generated an Operating Profit of about $47,000, versus an operating loss of $307,289 in Q2/18.

Yesterday, Verus International announced that it signed a revolving line of credit (LOC) with The Columbia Bank, N.A. (a Fulton Financial Corporation affiliate). The revolving credit line is immediately available for eligible foreign trade financing.

Verus International can immediately start to deploy this source of funds for new business. Based on current average inventory turns, Verus believes that the LOC can generate from $7M to $10M in annual revenue (depending upon the product mix). In addition to this agreement, the Company is also exploring other vendor and trade relationships, which can increase its growth trajectory through favorable terms that help minimize the financing for each shipment.

Verus International, Inc. (VRUS), closed Friday's trading session at $0.0199, off by 13.1004%, on 17,765,361 volume with 270 trades. The average volume for the last 3 months is 10,590,492 and the stock's 52-week low/high is $0.001399999/$0.037300001.

chart

Bonterra Resources, Inc. (BONXF)

Wall Street Nation, Proactive Investors, Stock Junction, MiningFeeds, Stockwatch, Investing News, Stockhouse, Minestat, and Junior Mining Network reported beforehand on Bonterra Resources, Inc. (BONXF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Bonterra Resources, Inc. is a gold exploration company listed on the OTCQX. The Company has a large balanced portfolio of exploration and mining assets. These include the Gladiator, Barry and Moroy deposits, Urban-Barry Mill and multiple highly prospective exploration prospects. Incorporated in 2007, Bonterra Resources has its head office in Val-d’Or, Québec.

Bonterra controls the only permitted gold mill in the area with a large land position of about 20,815 hectares in the Urban Barry Camp. Bonterra is situated in the mining-friendly Province of Québec, within the Abitibi Greenstone Belt.

The Urban-Barry Mill is connected to the provincial power grid, has high-speed Internet and cell phone service with an all-season camp for workers. Bonterra Resources’ plan is to expand the existing mill to 2,400 tonnes per day by the second half of 2019.

The Moroy Deposit is a south-parallel system to the Bachelor mine dipping north towards the Bachelor trend with potential to intersect the main trend at depth. Development and drill programs are taking place at Moroy with greater than 65,000 m of surface and underground drilling completed so far. This year, Bonterra will update the NI 43-101 mineral resource estimate at the Moroy Deposit. Additionally, Bonterra has regional exploration at the Bart Zone, the Coniagas Zone, the Moss Zone, and the St. Cyr Zone.

Mineralization at Bonterra’s Barry Deposit has been identified 1,300 m along strike and 600 m at depth. The deposit remains open in all directions, where a minimum of three distinct sub-parallel gold bearing shear zones and secondary tension veins are mineralized. The Gladiator Deposit is a highly silicified and altered sheared mafic volcanics, locally exhibiting intrusions of syenite and quartz porphyry. Smoky quartz veining also occurs locally containing the bulk of the mineralization and free gold.

Bonterra Resources completed 15,947 meters of infill and exploration diamond drilling during the quarter ended February 28, 2019. The Company has retained the services of SGS Geostat to complete an NI 43-101 resource estimate and technical report on three deposits. The Company also engaged two engineering firms, one commissioned to design the Urban-Barry mill expansion, and one to increase the capacity of the tailings storage facility to 10 million tonnes.

In July, Bonterra Resources announced drill results from its continuing exploration campaign at the Gladiator and Barry Projects. The Company intersected 18.5 g/t Au over 3.0 m at Gladiator and 11.6 g/t Au over 2.9 m at Barry.

Bonterra Resources, Inc. (BONXF), closed Friday's trading session at $1.83, even for the day, on 29,705 volume with 39 trades. The average volume for the last 3 months is 55,989 and the stock's 52-week low/high is $0.223000004/$2.86999988.

chart

Leafbuyer Technologies, Inc. (LBUY)

TipRanks, New Cannabis Ventures, Pot Stock News, Daily Marijuana Observer, Insider Tracking, TradingView, Super Stock Screener, Micro Small Cap, Zacks, Stockwatch, News Planets, Proactive Investors, Wallet Investor, 4-Traders, Simply Wall St, TMX Money, InvestorsHub, and Stockhouse reported earlier on Leafbuyer Technologies, Inc. (LBUY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Leafbuyer Technologies, Inc. partners with cannabis dispensaries and product companies throughout the U.S. to bring the best legal cannabis deals to consumers. It operates an online platform for cannabis deals and specials, and information that connects consumers with dispensaries. Established in 2012, the Company’s shares trade on the OTC Markets Group’s OTCQB. An ancillary technology company, Leafbuyer Technologies is headquartered in Greenwood Village, Colorado.

The Company’s business plan includes expanding into every State in the U.S. As soon as a State changes its policy toward medical or recreational legalization, Leafbuyer has team members on the ground making sure consumers have access to exclusive opportunities and that dispensaries have optimized resources to reach and keep customers.

By way of its hyperlocal Dispensaries Near Me page on its website, consumers can find the nearest dispensary to their location. In addition, the cannabis Deals Near Me page helps visitors find high-quality products at the best prices. They can discover deals on products infused with THC (tetrahydrocannabinol) and CBD (cannabidiol) or non-infused accessories. If a customer is unsure what product they're looking for, there are simple filters to help them narrow down their search. Alternatively, they can use Leafbuyer’s Product Guide to learn about the industry's leading brands and products.

Last month, Leafbuyer Technologies announced that it commenced expansion into the Michigan medical and developing recreational cannabis market. In early July, the Company started implementation of its strategic plan for the Michigan market with digital and direct mail campaigns. These initiatives will be followed with regular, in-person visits to local dispensaries and participation in industry events in the coming months. A number of digital partners and traditional marketing channels were identified with implementation expected in early 2020 when legal, licensed recreational dispensaries open their doors.

This week, Leafbuyer Technologies announced the development of an all-encompassing mobile application. The multifunctional app has been in development for many months. A public release is anticipated this fall. This new application merges the functionality of Leafbuyer’s current deals and search technology with the Greenlight order ahead and delivery application. Blockchain wallet capabilities are being designed to integrate into the new application for Leafbuyer Technologies loyalty customers.

Leafbuyer Technologies, Inc. (LBUY), closed Friday's trading session at $0.17, off by 11.6424%, on 8,866,435 volume with 1,281 trades. The average volume for the last 3 months is 367,728 and the stock's 52-week low/high is $0.145099997/$2.40000009.

chart

MGT Capital Investments, Inc. (MGTI)

Zacks, Micro Small Cap, News Planets, TipRanks, Infront Analytics, Simply Wall St, Stockopedia, TradingView, 4-traders, PR Newswire, Stockwatch, GlobeNewswire, Insider Tracking, Super Stock Screener, TMX Money and Stockhouse reported earlier on MGT Capital Investments, Inc. (MGTI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

MGT Capital Investments, Inc. is a Bitcoin miner with operations at hosted facilities in the States of Colorado and Ohio. In addition, it has started construction of an owned facility in Georgia. The Company is pursuing an expansion model to secure low cost power and grow its crypto assets. At March 30, 2019, it owned and operated roughly 5,700 miners in Colorado and Ohio. MGT Capital Investments has its head office in Durham, North Carolina.

Unlike traditional currencies, Bitcoin operates on the basis of a “public ledger system”. For Bitcoin transactions to be confirmed, avoiding the same Bitcoin being spent twice, Bitcoin miners are needed. Bitcoin mining plays an intricate part in the Bitcoin Blockchain ecosystem. Without Bitcoin miners, the ability to keep the public ledger system correct would be impossible.

MGT Capital Investments first started mining Bitcoin in September of 2016, in Washington State. In 2017, MGT opened an additional mining facility in Northern Sweden, which it has since wound down. At the end of Q3 2018, in response to the underperformance of MGT’s Swedish facilities, management shifted its main operations to North America. The transition was made to materially decrease the Company’s costs while establishing the conditions for stable, long-term growth.

In October 2018 and early 2019, management located and announced new mining facilities in Colorado and Ohio, undertaking the process of relocating its Swedish miners to those new facilities. Last month, MGT determined to consolidate its activities going forward in Company-owned and managed facilities in LaFayette, Georgia.

Located adjacent to a utility substation, the several acre property has access to greater than 20 megawatts (MW) of low-cost power. MGT also ordered transformers with a total load capacity of 12.5 MW to accommodate the initial phase of the project. MGT has started the construction and physical site development.

On July 16, 2019, MGT Capital Investments ordered 1,100 Bitmain S17 Antminers from Bitmain. These are expected to ship from Malaysia in October 2019 without Chinese tariffs. Each miner is rated at a maximum 56 Th/s, allowing for greater than 60 Ph/s in computing strength.

Each miner uses 2,860 W of electricity per hour, allowing for much greater efficiency versus the Company's current inventory of Bitmain S9 miners. The total load capacity should slightly surpass 3.1 MW and is expected to be accommodated in LaFayette.

MGT Capital Investments, Inc. (MGTI), closed Friday's trading session at $0.042, off by 3.4483%, on 5,381,374 volume with 200 trades. The average volume for the last 3 months is 7,577,142 and the stock's 52-week low/high is $0.028/$0.80400002.

chart

Spearmint Resources, Inc. (SPMTF)

Junior Mining Network, Investing News, Investorx, MarketSmart Resources, InvestmentPitch, Geology for Investors, Wallet Investor, Stockhouse, Trading View, 4-Traders, Stockwatch, and Dividend Investor reported previously on Spearmint Resources, Inc. (SPMTF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Spearmint Resources, Inc. acquires, explores, and evaluates mineral properties in the United States and Canada. Its focus is on assembling a portfolio of low risk, high reward properties at the exploration stage and developing them to maximize shareholder value. An exploration stage enterprise, Spearmint Resources is headquartered in Vancouver, British Columbia (BC).

Spearmint Resources has recently acquired the 'El North 3' claims package. The new acreage will result in a contiguous land package totalling 17,593 acres bordering Garibaldi Resources Corp. in the Golden Triangle of BC.

Spearment’s present projects include a portfolio of prospects in the Golden Triangle of BC; the 'Golden Triangle Gold Prospects' consisting of six claims comprising 9,157 acres bordering GT Gold Corp, the 920 acre 'NEBA West' & 6,803 acre 'NEBA' Gold-Copper Prospects bordering Aben Resources Ltd., the 'Henry' Gold-Copper Prospect consisting of two contiguous claim blocks totaling 4,912 acres in the direct vicinity of Golden Ridge Resources Ltd., and the 17,593 acre 'EL North' Nickel-Copper Prospect consisting of six contiguous claims in the Eskay Creek Camp bordering Garibaldi Resources Corp.

The Company’s other BC projects include the 'Gold Mountain Prospects' comprising three separate claim blocks totaling 1,245 acres bordering Barkerville Gold Mines, the 'Safari' Copper-Gold Prospect comprising 9,007 contiguous acres in the northern Quesnel Trough in north-central BC directly bordering Serengeti Resources Inc., and the 'Hammernose' Gold Prospect consisting of 5,140 acres directly bordering the strategic alliance between Westhaven Ventures Inc. & Sable Resources Ltd. in the Spences Bridge Gold Belt in Southern BC.

Present projects also include the 'Chibougamau Vanadium Prospects' comprising 17,142 contiguous acres bordering the vanadium deposit of BlackRock Metal's (private) Ilmenite vanadium project and Vanadium One Energy Corp. and Spearmint's 'Clayton Valley Lithium Prospects' in Nevada consisting of two claim blocks totaling 1,160 acres bordering Pure Energy Minerals & Cypress Development Corp. where Spearmint's drill results have intersected Lithium values as high as 1,670 ppm Li.

The Company announced last month that it acquired the 'Prickle' claims package comprising 4,980 contiguous acres directly bordering Brixton Metals Corp.'s Thorn project in the Golden Triangle of British Columbia. Spearmint Resources reported in July on results of a recent stream sediment sampling program on its 5,140 acre Hammernose prospect, positioned alongside and easterly of the Coquihalla Highway, with the property roughly 19 km's south of Merritt, BC. The Company encountered positive gold and copper indicators on Its Hammernose Prospect in BC.

Mr. James Nelson, President of Spearmint Resources, said, "We are very encouraged with the initial results on the Hammernose property. The sampling returned positive results and we are immediately formulating plans for 'on-the-ground' follow-up towards defining and tightening up possible mineralized drill targets focused around the highest gold and copper values. … Not only is this prospect now moving up on our priority list, we are very active in the Golden Triangle as well and look forward [to] the majority of the work season there happening this summer."

Spearmint Resources announced that after receiving positive gold and copper indicators from a recently completed work program announced in a news release on July 18, 2019, it has decided to immediately increase the size of the Hammernose gold prospect.

Spearmint Resources, Inc. (SPMTF), closed Friday's trading session at $0.025, up 25.00%, on 5,000 volume with 1 trade. The average volume for the last 3 months is 19,814 and the stock's 52-week low/high is $0.000099999/$0.075699999.

chart

Vogogo, Inc. (VGGOF)

CryptoSwan, StockPulse, Stock Digest, Penny Stock Hub, OTC Markets, Stockwatch, Stockhouse, Wallet Investor, Investors Hangout, Midas Letter, and Wallmine reported beforehand on Vogogo, Inc. (VGGOF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Vogogo, Inc. currently operates its cryptocurrency mining activities in the Province of Québec and the Company is Canada’s fastest growing miner. This includes mining for cryptocurrencies for its own account and within mining pools. At present, its has approximately 23,000 Bitmain Antminer S9’s actively mining for its own account, producing around 295 Petahashes per second (PH/s) of hashing power. OTCQB-listed, Vogogo has its head office in Toronto, Ontario.

In addition, Vogogo develops hashrate optimization software and data center management software. Its proprietary software optimizes hashrate. The Company’s monitoring systems alert of any issues in the datacenter. Vogogo’s mission is to build applications and services that are vital to the Bitcoin ecosystem and its stakeholders. The Company’s vision is to quickly improve the usability of cryptocurrencies and blockchain applications and hasten their adoption.

Vogogo recently stated that, over the past 12 months (as of May 28, 2019), it increased its mining operations from 4,125 S9’s, which produced roughly 50 PH/s to approximately 23,000 S9’s and 295 PH/s. This represents more than 450 percent growth.

On April 29, 2019, the Régie de l’énergie in Québec issued its decision for the blockchain file, providing certainty pertaining to electricity rates for Vogogo in Québec. The Regulator confirmed Vogogo’s industrial hydro electric rates (LG and M) from Hydro Quebec will not be increased.

Vogogo has developed two modern cryptocurrency mining facilities powered with low-cost, clean energy. The design of its facilities are with the latest cryptocurrency mining data center techniques and optimizations. The Company’s facilities have been designed with modern electrical and HVAC techniques for cryptocurrency mining.

This week, Vogogo announced its rebrand to Cryptologic. The comprehensive rebranding emphasizes its concentration on cryptocurrency mining and related services. The rebrand includes a new logo, positioning, as well as website.

The Company filed articles of amendment to change its name from “Vogogo Inc.” to “Cryptologic Corp.” effective as of July 31, 2019. Effective at the market opening on July 31, 2019, it began trading under its new name on the Canadian Securities Exchange (CSE), with its common shares trading under the new stock symbol “CRY” and its 8% Extendible Convertible Debentures trading under the new stock symbol “CRY.DB”.

Vogogo, Inc. (VGGOF), closed Friday's trading session at $2.0155, up 0.946609%, on 230 volume with 2 trades. The average volume for the last 3 months is 181 and the stock's 52-week low/high is $0.897700011/$7.52699995.

chart

Where Food Comes From, Inc. (WFCF)

NetworkNewsWire, Quality Small Caps, Uptick Newswire, Whale Wisdom, Equity Clock, MicroCapClub, Zacks, Wall Street Analyzer, InvestorsHub, Stockhouse, and OTC Markets reported previously on Where Food Comes From, Inc. (WFCF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Where Food Comes From, Inc. is a trusted resource for independent, third-party verification of food production practices in North America. It provides verification and certification solutions for the agriculture, livestock, and food industries in the United States. By way of its IMI Global, International Certification Services, Validus Verification Services, SureHarvest, A Bee Organic and Sterling Solutions units, its solutions are used to verify food claims, optimize production practices and enable food supply chains with analytics and data driven insights. Where Food Comes From has its corporate office in Castle Rock, Colorado.

The Company serves beef and pork packers, organic producers and processors, and specialty retail chains. It offers third-party verification services to hundreds of claims, programs, as well as markets. If a business is looking to create a new program specific to their brand, as long as its process or claim can be standardized, Where Food Comes From can create an audit platform to measure it accurately and authentically.

Through proprietary technology and patented business processes, Where Food Comes From supports over 15,000 farmers, ranchers, vineyards, wineries, processors, retailers, distributors, trade associations, consumer brands and restaurants with a wide variety of value-added services. Its Where Food Comes From® retail and restaurant labeling program uses web-based customer education tools to connect consumers to the sources of the food they purchase.

The Company provides accurate and transparent information about the food we eat and how, where, and by whom it is produced. It establishes a link between consumers and the people who produce food. In addition, Where Food Comes From sells hardware; and develops software and provides services related to sustainability measurement and benchmarking, traceability, verification, and certification to the food and agriculture industries.

Where Food Comes From announced this past May the launch of Black Angus Verified Beef. This is a new verification program designed to reassure cattle buyers and beef consumers that the claims producers and marketers make about Black Angus beef are authentic. Black Angus Verified Beef is a sub-program of Breed Verified, IMI Global’s newly approved USDA Process Verified Program.

Recently, the IMI Global division of Where Food Comes From announced the first sale of cattle verified under the Company’s Black Angus Verified Beef program. Two hundred and forty (240) head of Black Angus cattle were sold recently at the Superior Cornbelt Video Auction in Council Bluffs, Iowa. In addition to being verified to the new IMI Global Black Angus Verified Beef program standard, IMI Global verified the calves to Source and Age, Non-Hormone Treated Cattle (NHTC), Verified Natural Beef (VNB), and the Global Animal Partnership (GAP) 5-Step Animal Welfare program.

Where Food Comes From, Inc. (WFCF), closed Friday's trading session at $1.75, even for the day, on 2,649 volume with 8 trades. The average volume for the last 3 months is 8,746 and the stock's 52-week low/high is $1.615/$2.50.

chart

Tower One Wireless Corp. (TOWTF)

Trading View, Investopedia, Investors Hangout, Emerging Growth, Barchart, Stock Syndicate, InvestorsHub, MarketWatch, Stockhouse, Zacks, Insider Financial, OTC Markets, YCharts, The Street, Marketwired, 4-Traders, and Dividend Investor reported earlier on Tower One Wireless Corp. (TOWTF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Tower One Wireless Corp.’s mission is to own and operate high-quality cellular network infrastructure sites in South American markets that are experiencing strong usage growth. The Company focuses chiefly on constructing towers in municipalities where there is limited or no cellular coverage. Established in 2015, Tower One Wireless has its head office in Vancouver, British Columbia.

Currently, Tower One Wireless is focused on 4G & 5G LTE infrastructure expansion in Latin America. The Company builds, owns and leases a portfolio of wireless infrastructure assets to wireless carriers on long term contracts. In Argentina and Colombia, it has a growing portfolio of existing tower assets. Pertaining to Services, Tower One Wireless offers Tower Construction, Site Acquisition and Zoning, Staffing, and RF and Technical Services as well as Electrical Services.

Tower One entered into an agreement to acquire a 100 percent interest in Process Cellular, Inc. (ProCell) as a wholly-owned subsidiary. ProCell has been operating out of Southern California for more than twenty years as a turnkey general contractor that specializes in the telecommunications industry & structural engineering/design. This strategic acquisition gives Tower One subsidiary Tower Construction and Technical Services (TCTS) considerable exposure to the California and Arizona markets.

Tower One Wireless has signed a Master Lease Agreement (MLA) with Telefonica a Mobile Network Operator in Colombia and Latin America.  With this MLA, Tower One Wireless will provide Telefonica with the use of its Colombian wireless tower infrastructure over a 10 year fixed term contract.

Recently, Tower One Wireless announced it raised $966,300 CAD via secured, subordinated bonds. The bonds were issued at $100 per bond. They bear a simple interest at a fixed rate of 10 percent per annum payable monthly on the last day of each month. The maturity date of the Bonds is three years from the date of Closing.

In addition, Tower One updated on the number of towers it has deployed or are under construction in Argentina, Colombia, and Mexico. The numbers as of December 2018 include Argentina 44 In-service towers, 18 collocations, and 30 towers under construction.

For Colombia, the Company has 28 In-service towers, 5 collocations, and10 towers under construction. For Mexico, Tower One has 7 In-service towers and 24 towers under  construction.

Tower One Wireless Corp. (TOWTF), closed Friday's trading session at $0.0598, up 36.2187%, on 88,187 volume with 17 trades. The average volume for the last 3 months is 55,691 and the stock's 52-week low/high is $0.035/$0.132499992.

chart

Dakota Territory Resource Corp. (DTRC)

InvestorsHub, Zacks, Market Screener, YCharts, TradingView, Stockhouse, Barchart, Simply Wall St, Uptick Newswire, Real Investment Advice, Innovative Marketing, OTC Markets Group, Ultimate Penny Stock, MarketWatch, The Street, Marketbeat, Dividend Investor, last19k, Wallet Investor, Corporate Information, and 4-Traders reported earlier on Dakota Territory Resource Corp. (DTRC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Dakota Territory Resource Corp.’s emphasis is on the acquisition and responsible exploration and development of high caliber gold properties in the Black Hills of South Dakota. The Company maintains 100 percent ownership of three gold properties encompassing roughly 4,059 acres. These include the Blind Gold, City Creek, and Homestake Paleoplacer Properties. All of these properties are in the heart of the Homestake District. OTCQB-listed, Dakota Territory Resource is headquartered in Reno, Nevada. 

The Company’s flagship property is the Blind Gold Property, which is a target for Tertiary-aged and Iron-formation gold mineralization. The Blind Gold Property is about four miles northwest and on structural trend with the historic Homestake Gold Mine.

The Homestake Gold Mine produced roughly 40 million ounces of gold through its 125-year production history. It is the largest iron-formation-hosted gold deposit in the world.  

Dakota Territory’s plan is to continue its sampling program along trend of the zone of high grade gold mineralization identified by the first pass surface sampling program conducted on its 100 percent owned Blind Gold Property. The program identified a zone of high-grade gold mineralization in the Mississippian-age Pahasapa Limestone on the surface, with a peak gold assay value of 9.44 grams per tonne.

The Homestake Paleoplacer Property consists of 13 unpatented lode mining claims. These are situated one-mile north of the Homestake Open Cut. Dakota based the acquisition of its Black Hills property position on more than 44 years of combined mining and exploration experience in the Homestake District.

The Company’s City Creek Property is a target for Homestake iron-formation gold mineralization. City Creek consists of 21 unpatented lode mining claims. These are positioned one-mile northeast of the Homestake Open Cut and one-mile northwest of the City of Deadwood.

Recently, Dakota Territory Resource announced the appointment of Mr. Lee Graber to the Company’s Strategic Advisory Committee. Mr. Graber has more than four decades of experience in the mining industry. This includes 23 years with Homestake Mining Company, one of the largest gold mining companies in the U.S. until it was acquired in 2002 by Barrick Gold Corporation.

As Homestake's Vice President responsible for corporate development, Mr. Graber initiated, managed, and closed manifold joint venture agreements, major acquisitions, and divestment transactions. After Homestake, Mr. Graber served as Managing Director, Mergers and Acquisitions, for Endeavour Financial Ltd.

Dakota Territory Resource Corp. (DTRC), closed Friday's trading session at $0.053, up 24.7059%, on 169,702 volume with 13 trades. The average volume for the last 3 months is 17,532 and the stock's 52-week low/high is $0.019999999/$0.191750004.

chart

Nutra Pharma Corp. (NPHC)

Serious Traders, PennyStocks24, StocksToBuyNow, Pumps and Dumps, Winston Small Cap, Streetwise Reports, MyBestStockAlerts, BUYINS.NET, UndiscoveredEquities, Wallstreetlivechat, and Innovative Marketing reported earlier on Nutra Pharma Corp. (NPHC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Nutra Pharma Corp. is a biotechnology company listed on the OTC Markets. The Company specializes in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. These include Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Nutra Pharma is marketing Nyloxin® and Pet Pain-Away™ in the Over-the-Counter (OTC) pain management market. Founded in 2000, Nutra Pharma is based in Coral Springs, Florida.

By way of its subsidiaries, the Company carries out basic drug discovery research and clinical development. The focus of its approach to drug discovery and the development of new therapeutic agents are based on specialized receptor-binding proteins found in nature, particularly those found in snake venom from the cobra.

Nutra Pharma’s leading drug candidates are RPI-78M and RPI-MN. Its MS drug RPI-78M was earlier granted Orphan Status by the Food and Drug Administration (FDA) for the treatment of Pediatric Multiple Sclerosis. Nutra Pharma’s RPI-MN inhibits the entry of many viruses known to cause severe neurological damage in diseases such as encephalitis and AIDS. RPI-MN is undergoing development initially for the treatment of HIV. RPI-78M is undergoing development for the treatment of multiple sclerosis (MS).

Additionally, Nutra Pharma looks for strategic licensing partnerships to reduce the risks associated with the drug development process. The Company’s holding, ReceptoPharm, is developing technologies to produce drugs for HIV and MS.

Nutra Pharma’s Designer Diagnostics subsidiary engages in the research and development (R&D) of diagnostic test kits designed to be used for the quick identification of infectious diseases. These include Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).

Nutra Pharma offers several drug products for sale for pain treatment. One is Nyloxin®, the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The Company has launched Luxury Feet. This is a new version and packaging of its OTC pain drug Nyloxin. Another product is Nyloxin Extra Strength. This is the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. Moreover, the Company has its Pet Pain-Away. This is the first OTC product to treat pain in companion animals without side effects. Pet Pain-Away is a homeopathic, non-narcotic, non-addictive, OTC pain reliever.

In September 2018, Nutra Pharma announced that its work with EuroAmerican IP, LLC resulted in a listing of its Nyloxin® product line on the website, www.GoVets.com. GoVets is the online marketplace under the National Veteran Small Business Coalition (NVSBC) to buy from VA-verified Service-Disabled Veteran-Owned Small Businesses (SDVOSBs).

With growing concern regarding consumers using opioid and acetaminophen-based pain relievers, Nyloxin® offers an alternative, which does not rely on opiates or non-steroidal anti-inflammatory drugs, known as NSAIDs, for their pain relieving effects. Nyloxin® has a well-defined safety profile.    

         

Nutra Pharma Corp. (NPHC), closed Friday's trading session at $0.0004, up 33.3333%, on 300,000 volume with 1 trade. The average volume for the last 3 months is 4,558,622 and the stock's 52-week low/high is $0.000099999/$0.001.

chart

Inception Mining, Inc. (IMII)

Stock Commander, Dividend Investor, Investors Hangout, Marketwired, Simply Wall St, Barchart, Streetwise Reports, PennyStocks24, Information Solutions Group, Charms Investments, YCharts, Street Insider, and 4-Traders reported earlier on Inception Mining, Inc. (IMII), and we report on the Company as well, here at the QualityStocks Daily Newsletter.  

Inception Mining, Inc. engages in the acquisition, exploration, and development of precious metal properties -  chiefly gold-related. Its primary target properties are those that have been the subject of historical exploration having considerable supporting data. OTCQB-listed, Inception Mining is headquartered in Murray, Utah.

The Company holds interest in the U.P. and Burlington Gold Mine. This includes two Federal patented mining claims in the County of Lemhi, Northwest of Salmon, Idaho. The U.P. and Burlington Mine is within the Salmon National Forest. The mine is considered to be within the Eureka Mining District. 

Clavo Rico Ltd. is Inception Mining’s wholly-owned subsidiary. It assumed management control of Clavo Rico’s operation, the Cerros Del Sur operation in Honduras, Central America. Clavo Rico has principal operations in Honduras. Clavo Rico operates two subsidiaries and holds other mining concessions. Inception Mining’s main mine is situated on the 200 hectare Clavo Rico Concession, in southern Honduras.

Inception Mining continues to make improvements in operations and recovery, along with increasing its ore resources at the Cerros del Sur operation. Mine management has secured more mineable properties on its concession. Several adjacent landowners have placed the surface rights of their lands under contract with the mine.

Inception Mining announced in August of 2014 that it entered into an Ore Processing Agreement with New Jersey Mill Joint Venture (NJ Mill), a floatation mill that can process 360 metric tonnes per day. The mill is in Kellogg, Idaho. NJ Mill will process Inception Mining's bulk samples.     

In October 2017, Inception Mining announced that it entered into a Joint Venture (JV) Agreement with Corpus Mining and Exploration Ltd., a company domiciled in the Turks and Caicos. The JV creates a new company, Corpus Gold LLC.

In September 2018, Inception Mining announced that it entered into a verbal cooperation agreement with Glen Eagle Resources, Inc. Under the terms of the cooperation agreement, Glen Eagle will process certain high-grade material contained in sulfides produced at the Clavo Rico Mine that cannot be heap leached at the Clavo Rico Mine site but can undergo processing at Glen Eagle’s Cobro Oro de Honduras processing facility. This cooperation agreement is beneficial for both companies because it enables the processing of certain high-grade material for processing that may not otherwise be processed.

Inception Mining, Inc. (IMII), closed Friday's trading session at $0.101, up 26.25%, on 7,001 volume with 4 trades. The average volume for the last 3 months is 29,192 and the stock's 52-week low/high is $0.000199999/$0.550000011.

chart

Orbital Tracking Corp. (TRKK)

OTCMagic, Stock Commander, Penny Stock General, Fast Money Alerts, Stock Shock and Awe, Stock Preacher, Beacon Equity Research, SuperStockTips, Penny Stock Finder, Penny Stock Craze, MicroCapDaily, SmallCap Network, InvestorSoup, and Shiznit Stocks reported on Orbital Tracking Corp. (TRKK),  and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

Orbital Tracking Corp. provides satellite-based tracking, services, and mobile voice and data communications services worldwide, via satellite, to commercial and government users. The Company completed a reverse merger and a subsequent $1.1 million equity capital raise in February of 2015. This created Orbital Tracking Corp., a publically listed organization including the operations of Global Telesat Communications Ltd., a UK corporation (GTCL). OTCQB-listed, Orbital Tracking is headquartered in Aventura, Florida. 

Orbital Tracking (as a newly combined entity) launched as a fully operational Mobile Satellite Solutions (MSS) business. It specializes in services related to the Globalstar satellite constellation. This includes ground station construction, simplex tracking services, and satellite telecommunications voice airtime. The Company operates different e-commerce retail and tracking sites where users around the world can buy satellite hardware and track assets in real-time on mobile devices or personal computers (PCs).  

Orbital Tracking’s subsidiaries, U.S.-based Orbital Satcom Corp. and European Union (EU)-based Global Telesat Communications Ltd., provide around the world distribution of a broad variety of portable satellite voice, data, and tracking solutions. Global Telesat Communications (GTC) is a supplier of mobile voice and data communications services via satellite. GTC provides equipment and airtime for use on all the major satellite networks. This includes Globalstar, Inmarsat, Iridium, and Thuraya, permitting users in remote locations to make phone calls, connect to the internet, and track assets or personnel anywhere globally.

Orbital Tracking further expanded its reach into new markets in 2018 through the opening of its first e-commerce storefront in Australia. Notable orders it received during Q1 2018 in terms of Sales Revenue included the supply of satellite terminals and airtime for use by a disaster preparedness organization and annual renewal of the UK’s Forestry Commission’s 750+ SPOT Gen3 messaging plans.

In November, Orbital Tracking announced that it was included on Deloitte’s Technology Fast 500™. This is a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy technology companies in North America. Orbital Tracking’s Revenue increased by 148 percent during the period measured.

Orbital Tracking’s Chief Executive Officer, Mr. David Phipps, said, "We are pleased to make our first entry on Deloitte’s Technology Fast 500 and to be amongst just 3 percent of companies recognized in the 2018 winners list in the communications sector.”

Orbital Tracking Corp. (TRKK), closed Friday's trading session at $0.49, up 48.4848%, on 1,703 volume with 3 trades. The average volume for the last 3 months is 656 and the stock's 52-week low/high is $0.150999993/$1.35000002.

chart

AEON Global Health Corp. (AGHC)

Amigo Bulls, Stock Target Advisor, Stockopedia, Investors Hangout, Penny Stock Hub, Stockwatch, Simply Wall St, Zacks, Stockhouse, InvestorsHub, YCharts, TradingView, The Street, Stockflare, and Dividend Investor reported on AEON Global Health Corp. (AGHC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

AEON Global Health Corp., together with its subsidiaries, provides a variety of clinical laboratory testing services in the United States. The Company provides diagnostic services in Cancer Genomics, Toxicology, Pharmacogenomics, as well as Health Technology Applications. AEON formerly went by the name Authentidate Holding Corp. It changed its name to AEON Global Health Corp. in January 2018. OTCQB-listed, AEON Global Health has its corporate office in Gainesville, Georgia.

The Company is the fastest growing clinical lab and healthcare services organization in the United States. It is first in healthcare technology research and development (R&D) where its proprietary methodologies provide expedited and highly accurate urine and oral fluid (saliva) test results. AEON’s chief business focus is providing a “personalized medicine” approach to laboratory testing services. This is to provide customers with actionable medical information.

AEON is an innovator in the genomic testing area. The Company has an extensive menu of genetic tests and a pipeline of additional molecular-based tests in development. It provides post contract customer support services. The design of AEON’s Telehealth Solutions is to improve outcomes and reduce hospital readmission through helping clinicians closely monitor patients with chronic illnesses. These include CHF, COPD and Diabetes.

Concerning Toxicology Testing, AEON Global Health provides accurate and fast quantitative testing of drug metabolite levels in urine and oral fluids. The Company’s testing covers more than 80 analytes and metabolites. Its HPLC-tandem mass spectrometry can analyze wider molecular weight and polarity ranges of analytes, providing better selectivity and sensitivity.

AEON Clinical Labs services include Cancer Genomics, Pharmacogenomics, Toxicology, and Women’s Health. Health Technologies services include Inscrybe®. This is a secure and simple interface. Inscrybe® enables physicians, nurses, hospital staff, and external care facilities or health insurers to send, receive, sign, and track healthcare records, supporting documents, patient discharge orders and referrals or lab results and images on the web or via electronic fax instead of transferring paper.

In May 2018, AEON Global Health announced it earned The Joint Commission’s Gold Seal of Approval® for Laboratory Services Accreditation by demonstrating continuous compliance with its performance standards. The Gold Seal of Approval is a symbol of quality, which reflects an organization’s commitment to providing safe and effective patient care.

AEON Global Health underwent a thorough onsite survey earlier in 2018. During the review, a Joint Commission expert surveyor evaluated compliance with laboratory standards related to a number of areas. This included document and process control, healthcare-associated conditions, risk reduction, as well as staff qualifications and competency. Additionally, the surveyor conducted onsite observations and interviews.

AEON Global Health Corp. (AGHC), closed Friday's trading session at $0.248, up 64.2384%, on 283 volume with 3 trades. The average volume for the last 3 months is 2,442 and the stock's 52-week low/high is $0.150000005/$0.959999978.

chart

Wealthcraft Capital, Inc. (WCCP)

OTC Markets, MarketWatch, InvestorsHub, 4-Traders, Stockhouse, Simply Wall St, WalletInvestor, Penny Stock Hub, Penny Stock Tweets, Barchart, Stock Target Advisor, InvestorPlace, and Silicon Investor reported on Wealthcraft Capital, Inc. (WCCP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Wealthcraft Capital, Inc. concentrates on the investment of capital in private companies, which are interested in expanding their business through gaining better access to capital, management consulting, as well as business development. Mr. Adam D. Sexton is the President and Chief Executive Officer (CEO) of the Company.

Mr. Sexton is an experienced business, entertainment, and digital media leader. He has wide-ranging experience launching and operating disruptive digital products and services for worldwide entertainment, technology industry leaders, as well as start-ups.

Wealthcraft Capital was previously known as Wealthcraft Systems, Inc. It changed its name to Wealthcraft Capital, Inc. in February of 2017. The Company’s shares trade on the OTC Markets Group’s OTCQB. Wealthcraft Capital has its corporate headquarters in Los Angeles, California.

Last week, WealthCraft Capital announced the acquisition of a majority interest in Geaux Industries in exchange for $1,000,000 of the Company’s common stock at market value. Geaux Industries is a provider of security services for commercial, retail and industrial customers, with customized services and special patrol methods applicable for the cannabis industry, 

Geaux Industries is licensed by the California Department of Consumer Affairs. For selected security operations, Geaux does business under the franchised name of Signal 88 Security. The exchange agreement provides for Wealthcraft Capital to acquire the minority interest, under certain terms and conditions.

Mr. Sexton said, “With the legalization of recreational cannabis in California on January 1, 2018, the Company believes that there is a significant market opportunity for Geaux Industries to be one of the leading providers of specialized security services.”

Geaux Industries will continue to address the market with inventive new technologies and services and creative business models for the traditional and non-traditional businesses.

At the closing, Wealthcraft Capital CEO, Adam Sexton, was appointed to fill a vacancy on the Board of Directors of Geaux Industries.

Wealthcraft Capital, Inc. (WCCP), closed Friday's trading session at $0.508, up 152.7363%, on 100 volume with 1 trade. The average volume for the last 3 months is 1,748 and the stock's 52-week low/high is $0.172000005/$0.899999976.

chart

The QualityStocks Company Corner

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, recently provided a working benchtop Ultra Shear Technology (“UST”) instrument to scientists at The Ohio State University. To view the full article, visit: http://nnw.fm/ZPn14.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Friday's trading session at $2.95, up 11.3208%, on 3,832 volume with 28 trades. The average volume for the last 3 months is 8,606 and the stock's 52-week low/high is $1.51999998/$4.0999999.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (US:TGODF) is pleased to announce that it has successfully renewed its Health Canada licences for the Company's Ancaster, Ontario facility until August 2022.  As per the Cannabis Regulations, these licences authorize TGOD to cultivate, process and sell cannabis from its Ancaster site.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Friday's trading session at $2.35, up 8.7963%, on 590,345 volume with 590 trades. The average volume for the last 3 months is 506,596 and the stock's 52-week low/high is $1.60699999/$7.89379978.

Recent News

chart

Willow Biosciences Inc. (CSE: WLLW)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (CSE: WLLW).

Willow Biosciences Inc. (CSE: WLLW) was highlighted among this week's additions to its cannabis /hemp stock directory for investors following the sector by Investorideas.com and there is a podcast to listen to on the subject http://ibn.fm/uHSFg.

Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (CSE: WLLW), closed Friday's trading session at $0.82, up 12.33%, on 47,868 volume. The average volume for the last 3 months is 67,669 and the stock's 52-week low/high is $ 0.6500/$5.2500.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Florida-based biotechnology company Earth Science Tech (OTCQB: ETST) was recently evaluated by InvestorPlace analyst Mark Putrino in an article titled, ‘7 Marijuana Penny Stocks I May Buy,’ which highlighted the notable business experience of ETST’s management team and advisory board (http://nnw.fm/2FmVE). To view the full article, visit: http://nnw.fm/zN5hU.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed Friday's trading session at $0.78, up 4.00%, on 77,546 volume with 48 trades. The average volume for the last 3 months is 52,043 and the stock's 52-week low/high is $0.300999999/$2.45000004.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CNSX:LXX) (OTCQX:LXRP) (“Lexaria” or the “Company”) announces it has retained Integra Consulting Group LLC (“Integra”) to provide investor relations services to the Company in compliance with regulatory guidelines. Integra partners with select underexposed and undervalued emerging growth company and leverages decades of market experience with a robust proprietary database to continuously maximize market visibility throughout their clients’ different development cycles.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Friday's trading session at $0.697508, up 0.505476%, on 57,183 volume with 38 trades. The average volume for the last 3 months is 81,562 and the stock's 52-week low/high is $0.600000023/$2.24.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) was featured today in the 420 with CNW by CannabisNewsWire. Early this week, officials from the Louisiana Department of Agriculture and Forestry (LDAF) announced that medical marijuana products could soon be available in licensed dispensaries as soon as next week. This news brings a sigh of relief to patients who have waited through endless delays since 2015 when voters approved a measure to legalize medical cannabis.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed Friday's trading session at $0.3731, up 5.3955%, on 223,334 volume with 46 trades. The average volume for the last 3 months is 190,162 and the stock's 52-week low/high is $0.330000013/$1.52999997.

Recent News

chart

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) this morning announced its receipt of subscriptions for a convertible debenture financing in the amount of $1,325,000. Per the update, the debentures will have a maturity date of two years from the Offering’s closing date (“Maturity Date”), and will bear interest from the date of closing at 10 percent per annum, payable monthly. To view the full press release, visit: http://nnw.fm/O1uA9.

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed Friday's trading session at $0.339, up 13.00%, on 29,795 volume with 16 trades. The average volume for the last 3 months is 14,724 and the stock's 52-week low/high is $0.009999999/$1.12999999.

Recent News

chart

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (OTCQB: SHRG) continues to realize growth following the implementation of its Blue Ocean Strategy. An article further discussing the company reads, “SHRG reported record sales of $85.9 million for its fiscal year ended April 30, 2019, in its SEC 10K filing (http://nnw.fm/H3rwX). To view the full article, visit: http://nnw.fm/Qv1rK.

Sharing Services Global Corporation (SHRG), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRG has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services Global Corporation ’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders – Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services Global Corporation , and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services Global Corporation , at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services Global Corporation (SHRG), closed Friday's trading session at $0.1699, up 6.1875%, on 25,999 volume with 4 trades. The average volume for the last 3 months is 13,438 and the stock's 52-week low/high is $0.1026/$0.3944.

Recent News

chart

VPR Brands, LP (VPRB)

The QualityStocks Daily Newsletter would like to spotlight VPR Brands, LP (VPRB).

VPR Brands LP (OTC: VPRB), a market leader in vaporizer technology in the cannabis space, is remaking the vaping experience with the premarket release of its newest innovative product, the HoneyStick Brand BeeBox Pro Device (http://nnw.fm/3Vihj). Also today, the company was featured in the 420 with CNW by CannabisNewsWire.

Florida-based VPR Brands, LP (VPRB) is an innovative technology holding company whose assets include patented atomization-related products and technology. VPR Brands' current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate their products within the vaping industry.

VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. The company's current product portfolio is comprised of the following:

  • GoldLine combines premium ingredients and extracts coupled with the newest in technology to achieve the ultimate selection of cannabidiol (CBD) and hemp-based products available anywhere. The product range is designed for a wide variety of consumers and features edibles such as gummies and pure honey stix, tinctures, pre-rolled flower, vapable products and creams. For more information please visit?www.cbdgoldline.com.
  • HoneyStick is a lifestyle brand that combines the features of high tech, high performance, dependability and affordability when it comes to upper tier vaporizers. HoneyStick was first to market in creating a Sub Ohm vaporizer to the latest Ripper and Plasma GQ. The HoneyStick team works with a vast network of growers, extractors and industry figures to bring the needs of patients and recreational users to life. HoneyStick is sold online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about HoneyStick, visit?www.vapehoneystick.com.
  • Helium brings the vaping experience to a new level with intense flavors that are steeped to perfection and chilled at 20 degrees below room temperature. Helium's chillers are scientifically proven to preserve flavor, freshness and aroma. Helium is in a 50ml durable and squeezable bottle with drip tip that is functional from the start, engineered to deliver 77 percent VG.
  • Vaporin delivers Sub Ohm series starter kits. Vaporin also provides an eye-catching display case with multi-packs of selected starter kits, coils and premium e-liquids for retail and dispensary operations.
  • Vaporx offers the most current, highest quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech, Samsung. Vaporx acts as an extension to a client's purchasing department, providing the option to schedule regular product mix refresh for maximum sales.
  • GoldLine Hemp products are developed specifically for the convenience store market segment. GoldLine Hemp-only products are created without CBD, providing an alternative product line for consumers who are not ready to experience CBD products but still want to take advantage of this rapidly expanding class of products. GoldLine Hemp-only edible Hemp Gummies debuted at the National Association of Convenience Stores (NACS) Expo in Las Vegas in October 2018 and are now being distributed nationwide. The U.S. convenience store industry, with more than 154, 000 stores nationwide, serves 160 million customers daily and has sales that are 10.8% of the total U.S. retail and food service sales. Visit?www.goldlinehemp.com?for more information about GoldLine Hemp-only products.
  • Vapor Store Direct in Fort Lauderdale, Florida, is one of the largest vaporizer and e-liquid wholesalers in the United States. Vapor Store Direct stocks internationally elite brands, vaporizers, tanks/atomizers, coils, e-liquid, e-cigarettes, batteries, glass and accessories.

Management Team

CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, Frija became the president and chief executive officer of Vapor Corp., one of the first U.S. importers and publicly traded electronic cigarette companies. In 2016, Frija purchased the brands and wholesale business assets from Vapor Corp., which is now owned by VPR Brands. Under his leadership, VPR Brands is pivoting toward cannabis products which is increasing sales and profit margins.

Dan Hoff, chief operating officer, has worked in the vaporizer and e-cigarette industry, serving in various positions at Vapor Corp., including overseeing the financial management, accounting functions, supply chain management, product design and development, and key vendor relations. He has played a pivotal role in building and expanding the cannabis-based products division at VPR Brands, which includes a turnkey OEM vapor solutions program available to farmers, cultivators and extractors. Hoff received his bachelor's degree from the University of Miami School of Business.

VPR Brands, LP (VPRB), closed Friday's trading session at $0.0492, up 10.3139%, on 20,072 volume with 1 trade. The average volume for the last 3 months is 60,195 and the stock's 52-week low/high is $0.032650001/$0.119999997.

Recent News

chart

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT)

The QualityStocks Daily Newsletter would like to spotlight Blue Hat Interactive Entertainment Technology (BHAT).

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) is a leading producer, developer and operator of augmented reality (AR) games and smart toys in China for children and young adults ages three to 23. The company’s product line includes interactive educational materials, mobile games and toys with mobile game features. Blue Hat’s mobile-connected entertainment platform enables the connection of physical items to mobile devices through wireless technologies, creating a unique interactive user experience.

Blue Hat Interactive Entertainment Technology (BHAT) is a cutting-edge creator, developer and operator of popular augmented reality (“AR”) interactive smart toys and educational games in China. Blue Hat’s mobile-connected entertainment platform connects physical items to mobile devices through wireless technologies, creating a unique interactive user experience in various mobile games, interactive educational materials and toys with mobile game features.

Blue Hat designs original toys and games that utilize augmented reality technology, motion capture technology, image recognition technology, voice control, light sense technology, infrared, levitation induction, and other trending scientific technologies to transverse the virtual with reality. Blue Hat creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. This combination provides users with a more natural form of human computer interaction, enhances a user’s perception of reality, and delivers a more immersive entertainment experience.

Proprietary Technology

Founded in 2010, Blue Hat’s proprietary technology, product research and development, marketing channels and brand operation are the cornerstones of the business. Blue Hat focuses on the combination of “online” and “offline” activity and the interaction between “entertainment” and “product” to create a high-tech entertainment platform combining mobile games and AR. With the help of computer graphics, motion capture technology, image recognition technology and visualization technologies, Blue Hat accurately “places” virtual objects into the physical world, creating a new and stimulating visual environment for users.

Blue Hat recently displayed a variety of its sci-tech products at the Guangzhou International Toy Exhibition in China including AR Racer, Elastic Bubbles, AR Space Track, AR Alloy Toy Car, AR Need a Spanking, 5D Animated Magic Aquarium, Bug Travelers, AR Picture Book and other interactive games and smart toys.

The company has multiple products in development including new generations of four primary product lines and two new product lines.

Patents and Copyrights

Blue Hat’s advanced AR technology in interactive entertainment is protected by 178 authorized patents with 44 patents in various stages of the application process.

Another 14 applications for Patent Cooperation Treaty, or PCT, have been filed for international patents. As of March 31, 2019, the company owns 645 copyrights for artwork, 71 registered trademarks and 27 software copyrights.

Sales and Marketing

There has been rapid growth in the toys and games industry in China over the last several years. Total retail sales of toys and games in China soared from RMB 111.8 billion in 2012 to RMB 276.5 billion in 2017 with an average annual growth rate of 19.9% in 2017. Blue Hat believes the company is well positioned with little competition as the toy industry rapidly shifts toward intelligent and interactive toys and games. Retail sales of electronic toys grew at 24% annually in 2017 while that of traditional toys grew at 7%.

In addition to a powerful ecommerce presence, Blue Hat has long-term relationships with partnered distributors that place the company’s AR interactive entertainment products into well-known international retail chains and retail outlets. Blue Hat’s integrated online and offline sales channels include e-commerce giants such as Amazon and Alibaba, retail chain stores and the company’s physical experience store located in Xiamen, China. Blue Hat plans to open or franchise approximately 100 additional stores in China by 2021.

Blue Hat’s community-based platform offers users a highly engaged and interactive community with online communication forums and offline social activities. The company advocates a new model of “teaching through lively activities” and combines AR technology with education, integrating its products into situational teaching, roleplaying and man-machine interaction. This novel educational experience helps realize optimal transformation of information, creating a knowledge and enhancing cognition.

Management

Director and CEO Xiaodong (Sean) Chen has over 20 years of experience creating, developing and producing toys and games related products. Chen earned his EMBA from Renmin University of China and has been chairman of the board of directors and general manager of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

CFO and Director Caifan, who has over 20 years of financial accounting and taxation experience, earned a degree in finance from Hunan University of Finance and Economics. He has served as director, deputy general manager and financial controller of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

Jianyong Cai, chief technology officer and director, has over 35 years of experience in data communication principles, communication network foundation, software engineering, communication network theory and technology and computer network architecture. He holds degrees in data communication principles, communication network foundation and software engineering from University of Science and Technology of China. He has been director, deputy general manager and chief engineer of Fujian Blue Hat Interactive Entertainment Technology Ltd. since January 2010.

Blue Hat Interactive Entertainment Technology (BHAT), closed Friday's trading session at $3.70, even for the day, on 49,836 volume with 169 trades. The average volume for the last 3 months is 558,860 and the stock's 52-week low/high is $3.65000009/$6.25.

Recent News

chart

INmune Bio Inc. (NASDAQ: INMB)

The QualityStocks Daily Newsletter would like to spotlight INmune Bio Inc. (NASDAQ: INMB).

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight disease, presented its innovative cancer immunotherapy, as well as its Alzheimer’s disease drug candidate, during a major immunotherapy industry congress.

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient's innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease. INmune Bio's product platforms utilize a precision therapy approach to promote the body's innate immune response to treat unsolved problems in medicine.

INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a "Part the Cloud" award from the Alzheimer's Association in 2018 which included a $1 million grant to advance INmune Bio's XPro1595 drug candidate.

INmune Bio's product pipeline targets three segments of concern:

  • Alzheimer's disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer's as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
  • Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer ("NK") cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
  • Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.

INmune Bio Drug Candidates and Clinical Programs

INKmune is a biologic delivery system that primes a patient's resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.

In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease ("MRD").

Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease.

INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells ("MDSC") which can produce an immunosuppressive shield that prevents a patient's own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.

Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer's disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer's.

The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer's disease who have neuroinflammation. The trial is supported by a $1 million "Part the Cloud" grant from the Alzheimer's Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer's disease.

Management

Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.

CFO David J. Moss co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor's degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.

Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company's formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum's research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer's Association. He received his Ph.D. in neuroscience from Binghamton University.

INmune Bio Inc. (OTC: INMB), closed Friday's trading session at $8.82, even for the day, on 12,268 volume with 77 trades. The average volume for the last 3 months is 12,953 and the stock's 52-week low/high is $7.00/$11.50.

Recent News

chart

Spectrum Global Solutions, Inc. (SGSI)

The QualityStocks Daily Newsletter would like to spotlight Spectrum Global Solutions, Inc. (SGSI).

Leading telecommunications engineering and infrastructure services provider Spectrum Global Solutions (OTCQB: SGSI) recently announced the acquisition of German energy, infrastructure technology company WaveTech GmbH (http://nnw.fm/kqM1B). To view the full article, visit: http://nnw.fm/d5dzN.

Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

  • AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
  • ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
  • Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.

Management

CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

Spectrum Global Solutions, Inc. (SGSI), closed Friday's trading session at $0.036, even for the day, on 23,625 volume. The average volume for the last 3 months is 125,923 and the stock's 52-week low/high is $0.032000001/$2.5999999.

Recent News

chart

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics (OTCQB: ENDV) is a developer of safe, wearable and non-invasive medical devices. The company’s SofPulse(R) device targets inflammatory conditions in both the organs and the peripheral tissues. To view the full article, visit: http://nnw.fm/I6xxj.

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s?targeted?pulsed electromagnetic field?(tPEMF)?transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone.?

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.?

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Endonovo Therapeutics Inc. (ENDV), closed Friday's trading session at $0.0107, off by 4.4643%, on 3,349,078 volume with 42 trades. The average volume for the last 3 months is 6,398,831 and the stock's 52-week low/high is $0.008999999/$0.066100001.

Recent News

chart

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: NABIF).

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P), a leading Canadian investment company with specialty investments in assets across multiple divisions of the cannabis sector, has secured an entry point into the world’s largest cannabis industry market through the purchase of a dispensary in California. To view the full article, visit: http://nnw.fm/cdtL2.

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."

Strategy

While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: NABIF), closed Friday's trading session at $0.12412, off by 24.593%, on 44,182 volume with 22 trades. The average volume for the last 3 months is 47,993 and the stock's 52-week low/high is $0.119249999/$0.791499972.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.